Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Combination of minimally invasive surgery and carboplatin for stage IIa seminoma

In this video, Robert Huddart, MBBS, MRCP, FRCR, PhD, of The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, evaluates the efficacy of minimally invasive retroperitoneal lymph node dissection (MI-RPLND) in stage IIa seminoma (SEM) patients. Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof. Huddart reports that MI-RPLND used in conjunction with adjuvant carboplatin is a promising treatment option for stage IIa SEM.